LEGN insider trading
NasdaqGS HealthcareLegend Biotech Corp: insider trade history from SEC Form 4 filings.
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Company website: legendbiotech.com
LEGN insider activity at a glance
FilingIQ tracks 15 insider transactions for LEGN in filings since Mar 27, 2026. The most recent transaction is dated Sep 29, 2026.
Across the full history, 0 open-market purchases
and 5 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on LEGN insider trades is 64.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest LEGN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for LEGN?
- FilingIQ tracks 15 Form 4 insider transactions for LEGN (Legend Biotech Corp), covering filings from Mar 27, 2026 onwards. 11 of those are dated within the last 90 days.
- Are LEGN insiders net buyers or net sellers?
- Across the full Form 4 history for LEGN, 0 transactions (0%) were open-market purchases and 5 (33%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does LEGN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is LEGN in?
- Legend Biotech Corp (LEGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.11B.
Methodology & sources
Every LEGN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.